Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Total Current Liabilities (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Total Current Liabilities readings, the most recent being $3.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 45.29% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, down 45.29%, and an annual FY2025 reading of $3.1 million, down 45.29% over the prior year.
  • Total Current Liabilities hit $3.1 million in Q4 2025 for Lisata Therapeutics, down from $4.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $6.6 million in Q4 2023, with the low at $3.1 million in Q4 2025.
  • Median Total Current Liabilities over the past 3 years was $4.6 million (2024), compared with a mean of $4.8 million.
  • The sharpest move saw Total Current Liabilities rose 2.32% in 2024, then crashed 45.29% in 2025.
  • Year by year, Total Current Liabilities stood at $6.6 million in 2023, then dropped by 14.83% to $5.6 million in 2024, then tumbled by 45.29% to $3.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $3.1 million, $4.6 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.